Weekly Investment Analysts’ Ratings Changes for Baxter International (BAX)

A number of firms have modified their ratings and price targets on shares of Baxter International (NYSE: BAX) recently:

• 1/21/2026 – Baxter International had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 1/20/2026 – Baxter International was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating.
• 1/17/2026 – Baxter International was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 1/9/2026 – Baxter International had its price target raised by analysts at The Goldman Sachs Group, Inc. from $22.00 to $23.00. They now have a “neutral” rating on the stock.
• 1/9/2026 – Baxter International had its price target lowered by analysts at Barclays PLC from $36.00 to $30.00. They now have an “overweight” rating on the stock.
• 1/5/2026 – Baxter International had its price target lowered by analysts at Evercore ISI from $24.00 to $23.00.
• 12/12/2025 – Baxter International had its price target lowered by analysts at Wells Fargo & Company from $21.00 to $19.00. They now have an “equal weight” rating on the stock.
• 12/2/2025 – Baxter International had its price target lowered by analysts at Morgan Stanley from $19.00 to $15.00. They now have an “underweight” rating on the stock.
• 12/1/2025 – Baxter International was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating.

Baxter International Cuts Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 2nd. Stockholders of record on Friday, November 28th were paid a dividend of $0.01 per share. The ex-dividend date of this dividend was Friday, November 28th. This represents a $0.04 annualized dividend and a dividend yield of 0.2%. Baxter International’s payout ratio is -6.06%.

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.